An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Name
STM Manuscript _Jonas_et_al_2015.pdf
Size
1.63 MB
Format
Adobe PDF
Checksum (MD5)
bd79061176818a90718ac6d334a20323
Author(s)
Jonas, Oliver H.
Landry, Heather M.
Fuller, Jason E.
Cima, Michael J.
Santini, John T., Jr.
Baselga, Jose
Tepper, Robert I.
Langer, Robert S
Date Issued
April 2015
Journal
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Jonas, O., H. M. Landry, J. E. Fuller, J. T. Santini, J. Baselga, R. I. Tepper, M. J. Cima, and R. Langer. “An Implantable Microdevice to Perform High-Throughput in Vivo Drug Sensitivity Testing in Tumors.” Science Translational Medicine 7, no. 284 (April 22, 2015): 284ra57–284ra57.
Version
Author's final manuscript
Abstract
Current anticancer chemotherapy relies on a limited set of in vitro or indirect prognostic markers of tumor response to available drugs. A more accurate analysis of drug sensitivity would involve studying tumor response in vivo. To this end, we have developed an implantable device that can perform drug sensitivity testing of several anticancer agents simultaneously inside the living tumor. The device contained reservoirs that released microdoses of single agents or drug combinations into spatially distinct regions of the tumor. The local drug concentrations were chosen to be representative of concentrations achieved during systemic treatment. Local efficacy and drug concentration profiles were evaluated for each drug or drug combination on the device, and the local efficacy was confirmed to be a predictor of systemic efficacy in vivo for multiple drugs and tumor models. Currently, up to 16 individual drugs or combinations can be assessed independently, without systemic drug exposure, through minimally invasive biopsy of a small region of a single tumor. This assay takes into consideration physiologic effects that contribute to drug response by allowing drugs to interact with the living tumor in its native microenvironment. Because these effects are crucial to predicting drug response, we envision that these devices will help identify optimal drug therapy before systemic treatment is initiated and could improve drug response prediction beyond the biomarkers and in vitro and ex vivo studies used today. These devices may also be used in clinical drug development to safely gather efficacy data on new compounds before pharmacological optimization.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1126/scitranslmed.3010564
